Table 3.
Serious adverse event (SAE) reports of SARS-CoV-2 neutralizing monoclonal antibodies from 2020 to 2022
| Total n (%) | Bamlanivimab n (%) | Casirivimab/Imdevimab n (%) | Bamlanivimab/Etesevimab n (%) | Sotrovimab n (%) | Bebtelovimab n (%) | Tixagevimab/Cilgavimab n (%) | |
|---|---|---|---|---|---|---|---|
| Adverse event (AE) | |||||||
| Non-serious | 17,815 (41.8) | 7798 (50.6) | 2942 (19.3) | 890 (30.6) | 4357 (97.1) | 1355 (100) | 473 (14.6) |
| Serious | 24,827 (58.2) | 7605 (49.4) | 12,310 (80.7) | 2023 (69.4) | 130 (2.9) | 0 (0.0) | 2759 (85.4) |
| Type of SAE | |||||||
| Death | 1289 (5.2) | 503 (6.6) | 328 (2.7) | 50 (2.5) | 19 (14.6) | 0 (0.0) | 389 (14.1) |
| Life-threatening | 979 (3.9) | 259 (3.4) | 513 (4.2) | 95 (4.7) | 3 (2.3) | 0 (0.0) | 109 (4.0) |
| Hospitalization | 10,965 (44.2) | 4546 (59.8) | 4950 (40.2) | 600 (29.7) | 41 (31.5) | 0 (0.0) | 828 (30.0) |
| Disability | 220 (0.9) | 24 (0.3) | 105 (0.9) | 15 (0.7) | 1 (0.8) | 0 (0.0) | 75 (2.7) |
| Congenital anomaly/birth defect | 6 (0.02) | 2 (0.0) | 4 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Required intervention to prevent permanent impairment/damage | 2167 (8.7) | 222 (2.9) | 1301 (10.6) | 505 (25.0) | 7 (5.4) | 0 (0.0) | 132 (4.8) |
| Others | 9201 (37.1) | 2049 (26.9) | 5109 (41.5) | 758 (37.5) | 59 (45.4) | 0 (0.0) | 1226 (44.4) |